eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac
Portal dla gastroenterologów!
SCImago Journal & Country Rank
vol. 13
Poleć ten artykuł:
streszczenie artykułu:
Artykuł oryginalny

Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4

Dorota Kozielewicz, Anna Grabińska, Grzegorz Madej, Magdalena Wietlicka-Piszcz

Data publikacji online: 2018/03/26
Pełna treść artykułu
Pobierz cytowanie
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero

Dual therapy (PegIFN and ribavirin) (DT) was the standard of care in patients infected with HCV genotype 4 (HCV-4) until 2014. Nowadays, new treatment options are available including interferon (IFN)-based and other IFN-free regimens.

To assess the efficacy (SVR24) and safety of DT and the selected predictor factors of SVR in HCV-4 infected patients.

Material and methods
One hundred and twelve patients (62 men) of median age 23 years were treated with DT for 48/72 weeks (107/5) in the years 2006–2014. Most of them were treatment naïve (80.4%) and with fibrosis F ≤ 2 (83.1%). To select a subset of independent predictors of SVR Logistic Regression Analysis was applied.

SVR24 was achieved in 46/112 (41.1%) patients. The mean viral load was 5.55 log10 IU/ml. Lack of therapy experience increases the odds of achieving SVR (OR = 4.17; 1.04–16.67), whereas more advanced fibrosis and higher baseline viral load tend to decrease the probability of SVR (OR = 0.05; 0.01–0.52 and OR = 0.44; 0.17–1.13, respectively). In contrast, the weight loss is associated with higher probability of virological response (OR = 4.31; 1.37–13.60). Two hundred and seventy-nine adverse events (AEs) were reported in 96 individuals. The rates and types of AEs were similar in patients treated with PegIFN-α2a/RBV and PegIFN-α2b/RBV. Overall, 3 (2.7%) patients discontinued therapy prematurely because of serious AEs.

SVR24 was low. Loss of weight was a new positive predictive factor of SVR found in our study. Most of the AEs were typical of those previously reported for DT.

Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107-15.
Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Inter 2011; 31: 30-61.
Blachier M, Leleu H, Peck-Radosavljevic M, et al. The burden of liver disease in Europe, a review of available epidemiological data. J Hepatol 2013; 58: 593-608.
Panasiuk A, Flisiak R, Mozer-Lisewska I, et al. Distribution of HCV genotypes in Poland. Przegl Epidemiol 2013; 67: 99-103.
Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014; 59: 318-27.
Khattab MA, Ferenci P, Hadziyannis SJ, et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 2011; 54: 1250-62.
EASL Clinical Practice Guidelines: management of hepatitis C virus Infection. J Hepatol 2014; 60: 392-420.
Halota W, Flisiak R, Boroń-Kaczmarska A, et al. Recommendations for the treatment of hepatitis C issued by the Polish Group of HCV Experts 2016. Clin Exp Hepatol 2016; 2: 27-33.
EASL Recommendation on Treatment of Hepatitis C 2015. J Hepatol 2015; 63: 199-236.
Doss W, Esmat G, El-Sefary M, et al. Real-life result of sofosbuvir based therapy for Egyptian patients with hepatitis C and advanced fibrosis-cirrhosis. J Hepatol 2016; 64 (Suppl 2): S772.
Cianciara J, Juszczyk J, Halota W. Konsensus dotyczący leczenia wirusowego zapalenia wątroby typu C. Mrągowo, 3 czerwca 2006 r. Przegl Epidemiol 2006; 60: 749-50.
Roulot D, Bourcier V, Grando V, et al. Observational VHC4 Study Group. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007; 14: 460-7.
Papastergiou V, Dimitroulopoulos D, Skorda L, et al. Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: does ethnicity matter? J Med Virol 2012; 84: 1217-23.
Haushofer AC, Kopty C, Hauer R, et al. HCV genotypes and age distribution in patients of Vienna and surrounding areas. J Clin Virol 2001; 20: 41-7.
Trapero-Marugan M, Moreno-Monteagudo JA, Garcia-Buey L, et al. Clinical and pathological characteristics and response to combination therapy of genotype 4 chronic hepatitis C patients: experience from a Spanish center. J Chemother 2007; 19: 423-7.
Buti M, Franco A, Carmona I, et al. Profiles and clinical management of hepatitis C patients in Spain: disHCovery study. Rev Esp Quimioter 2015; 28: 145-53.
Urquijo JJ, Diago M, Boadas J, et al. Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4. Ann Hepatol 2013; 12: 30-5.
Anagnostou O, Manolakopoulos S, Bakoyannis G, et al. Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study. Hippokratia 2014; 18: 57-64.
Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology 2010; 132: 503-12.
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe